AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14569643 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 208
Study 14569643 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 208
Study 10383563 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS amitriptyline (75 mg)
Number of subjects: 14
Study 10383563 — intervention group
Group type: COMPARATOR
Intervention: IR amitriptyline (25 mg every 8 h)
Number of subjects: 14
Study 10383563 — intervention group
Group type: COMPARATOR
Intervention: IR amitriptyline (3x25 mg at nighttime)
Number of subjects: 14
Study 8696988 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic patients with organ dysfunction (OD)
Number of subjects: 49
Study 8696988 — intervention group
Group type: COMPARATOR
Intervention: Septic patients without organ dysfunction (OD)
Number of subjects: 49
Study 8696988 — intervention group
Group type: COMPARATOR
Intervention: Postgastrectomy patients
Number of subjects: 49
Study 2060151 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodide supplementation (500 micrograms/day for 28 days)
Number of subjects: 225
Study 2060151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 29736491 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement (RM-GIC)
Number of subjects: 18
Study 29736491 — intervention group
Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 18
Study 27064959 — intervention group
Group type: EXPERIMENTAL
Intervention: Head turn preference
Number of subjects: 70
Study 25154949 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal insertion
Number of subjects: 44
Study 25154949 — intervention group
Group type: COMPARATOR
Intervention: Distal insertion
Number of subjects: 44
Study 22646230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemia intervention (goal A1C <6.0%)
Number of subjects: 0
Study 22646230 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemia intervention (goal A1C 7‐7.9%)
Number of subjects: 0
Study 20439595 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of Gardasil, Menactra, and Adacel (group A)
Number of subjects: 1042
Study 20439595 — intervention group
Group type: COMPARATOR
Intervention: Nonconcomitant administration of Gardasil, Menactra, and Adacel (group B)
Number of subjects: 1042
Study 18161643 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge telephone intervention to encourage compliance with aftercare
Number of subjects: 282
Study 16906786 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily regimen of efavirenz, emtricitabine and tenofovir DF (administered as individual agents)
Number of subjects: 517
Study 16906786 — intervention group
Group type: COMPARATOR
Intervention: Co-formulated efavirenz/emtricitabine/tenofovir DF
Number of subjects: 517
Study 12707093 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial-dose doxycycline (20-mg tablets taken twice daily for 6 months)
Number of subjects: 51
Study 12707093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 11123824 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel at 60 mg/kg divided into two doses
Number of subjects: 253
Study 11123824 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel at a single dose of 40 mg/kg
Number of subjects: 253
Study 9181384 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate (A/C) 70/10 mg/kg/day given b.i.d.
Number of subjects: 463
Study 9181384 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate (A/C) 60/15 mg/kg/day given t.i.d.
Number of subjects: 463
Study 8233391 — intervention group
Group type: COMPARATOR
Intervention: Argon laser scatter (panretinal) photocoagulation
Number of subjects: 696
Study 8233391 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton laser scatter (panretinal) photocoagulation
Number of subjects: 696
Study 2418659 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin intravesical instillation (60 mg on each treatment day)
Number of subjects: 124
Study 2418659 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin + Bestatin (60 mg per day)
Number of subjects: 124
Study 31849295 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (569 patients)
Number of subjects: 750
Study 31849295 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet function testing (PFT)
Number of subjects: 750
Study 31849295 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 750
Study 31849295 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 myocardial infarction (T2MI)
Number of subjects: 750
Study 30201679 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS) intervention implemented in family medicine clinics
Number of subjects: 71
Study 30201679 — intervention group
Group type: COMPARATOR
Intervention: Control group (general internal medicine clinics)
Number of subjects: 71
Study 26253874 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 90
Study 26253874 — intervention group
Group type: COMPARATOR
Intervention: No Amiodarone
Number of subjects: 90
Study 25403709 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised dietetic advice and regular weekly follow-up (INT)
Number of subjects: 120
Study 25403709 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC) with provision of nutrition education materials only
Number of subjects: 120
Study 21935656 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pulse pressure in patients with Killip Class II‐IV heart failure
Number of subjects: 1955
Study 19798046 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 18
Study 18521509 — intervention group
Group type: EXPERIMENTAL
Intervention: activated prothrombin complex concentrate (aPCC)
Number of subjects: 48
Study 18521509 — intervention group
Group type: COMPARATOR
Intervention: recombinant factor VIIa (rFVIIa)
Number of subjects: 48
Study 15688388 — intervention group
Group type: EXPERIMENTAL
Intervention: Automation-assisted screening
Number of subjects: 471297
Study 15688388 — intervention group
Group type: COMPARATOR
Intervention: Conventional screening
Number of subjects: 471297
Study 12219472 — intervention group
Group type: COMPARATOR
Intervention: Combination of antioxidants and zinc
Number of subjects: 3600
Study 12219472 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic treatment of certain forms of CNV
Number of subjects: 3600
Study 12219472 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic laser treatment of soft drusen maculopathy
Number of subjects: 3600
Study 12219472 — intervention group
Group type: COMPARATOR
Intervention: Visual rehabilitation using eccentric viewing
Number of subjects: 3600
Study 9926184 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (3.0 mg.kg‐1)
Number of subjects: 281
Study 9926184 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.3 mg.kg‐1)
Number of subjects: 281
Study 9926184 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.2 ml.kg‐1)
Number of subjects: 281
Study 9926184 — intervention group
Group type: COMPARATOR
Intervention: Pethidine (1.5 mg.kg‐1)
Number of subjects: 281
Study 9926184 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 281
Study 7486039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.10 mg/kg, 2 x ED95) administered over 60 s (Pilot Group A, n = 5)
Number of subjects: 70
Study 7486039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.10 mg/kg, 2 x ED95) administered over 30 s (Pilot Group B, n = 5)
Number of subjects: 70
Study 7486039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.10 mg/kg, 2 x ED95) administered over 5-10 s (Group C, n = 30)
Number of subjects: 70
Study 7486039 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (0.10 mg/kg, 2 x ED90) administered over 5-10 s (Group D, n = 30)
Number of subjects: 70
Study 2208633 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole 400mg/d x 3d
Number of subjects: 720
Study 2208633 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole 400mg/d x 5d
Number of subjects: 720
Study 2208633 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrantel 1,500mg/d x 3d
Number of subjects: 720
Study 2208633 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrantel 1,500mg/d x 5d
Number of subjects: 720
Study 2208633 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole 400mg/d x 3d or 5d
Number of subjects: 720
Study 6161273 — intervention group
Group type: EXPERIMENTAL
Intervention: vinblastine/bleomycin
Number of subjects: 74
Study 6161273 — intervention group
Group type: EXPERIMENTAL
Intervention: adriamycin/cis-dichlorodiammineplatinum (II) (DDP)
Number of subjects: 74
Study 6161273 — intervention group
Group type: EXPERIMENTAL
Intervention: surgical removal of residual pulmonary metastases
Number of subjects: 74
Study 6161273 — intervention group
Group type: EXPERIMENTAL
Intervention: complete responders
Number of subjects: 74
Study 6161273 — intervention group
Group type: COMPARATOR
Intervention: all other patients
Number of subjects: 74
Study 6161273 — intervention group
Group type: EXPERIMENTAL
Intervention: overall survival
Number of subjects: 74
Study 6161273 — intervention group
Group type: EXPERIMENTAL
Intervention: advanced abdominal disease, elevated beta-HCG, LDH, extension of pulmonary disease
Number of subjects: 74
Study 31182874 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (1 mg/kg of weight)
Number of subjects: 60
Study 31182874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28743341 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal aorta pressure group
Number of subjects: 40
Study 28743341 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 25494869 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training only (E)
Number of subjects: 27
Study 25494869 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance and strength training (E+S)
Number of subjects: 27
Study 25494869 — intervention group
Group type: COMPARATOR
Intervention: Endurance training only (E) and Endurance and strength training (E+S)
Number of subjects: 27
Study 23494656 — intervention group
Group type: EXPERIMENTAL
Intervention: rhLAMAN (recombinant human alpha-mannosidase) administered weekly via intravenous enzyme replacement therapy (ERT) for 12 months
Number of subjects: 10
Study 21644300 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongluo Guben needling method (observation group)
Number of subjects: 132
Study 21644300 — intervention group
Group type: COMPARATOR
Intervention: Control group (Shenshu, Dachangshu, Huantiao, Chengfu)
Number of subjects: 132
Study 21644300 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (VAS and ODI scales)
Number of subjects: 132
Study 19607770 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 0
Study 19607770 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 19607770 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 19607770 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 0
Study 19607770 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 0
Study 19607770 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% patch
Number of subjects: 0
Study 16424422 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 14
Study 16424422 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic albuterol
Number of subjects: 14
Study 16424422 — intervention group
Group type: EXPERIMENTAL
Intervention: R-albuterol
Number of subjects: 14
Study 12814158 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol single inhaler (Symbicort Turbuhaler) 160/4.5 microg delivered dose, two inhalations bid
Number of subjects: 321
Study 12814158 — intervention group
Group type: COMPARATOR
Intervention: Budesonide plus formoterol via separate inhalers
Number of subjects: 321
Study 12814158 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol single inhaler (Symbicort Turbuhaler)
Number of subjects: 321
Study 10608768 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg/kg of recombinant human (rh) IL‐10
Number of subjects: 49
Study 10608768 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 49
Study 8858433 — intervention group
Group type: EXPERIMENTAL
Intervention: Three group discussion sessions
Number of subjects: 3
Study 8858433 — intervention group
Group type: EXPERIMENTAL
Intervention: Three sessions of caring for a PWA
Number of subjects: 3
Study 8858433 — intervention group
Group type: COMPARATOR
Intervention: Assessment materials only
Number of subjects: 3
Study 1536399 — intervention group
Group type: EXPERIMENTAL
Intervention: Human albumin solution
Number of subjects: 475
Study 1536399 — intervention group
Group type: COMPARATOR
Intervention: 3.5% polygeline
Number of subjects: 475
Study 6379911 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendamistate 400 mg
Number of subjects: 10
Study 6379911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31166390 — intervention group
Group type: EXPERIMENTAL
Intervention: ECA coating on the surface before sterilization (ECA1)
Number of subjects: 48
Study 31166390 — intervention group
Group type: EXPERIMENTAL
Intervention: ECA coating after sterilization (ECA2)
Number of subjects: 48
Study 31166390 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG), no surface treatment
Number of subjects: 48
Study 31166390 — intervention group
Group type: EXPERIMENTAL
Intervention: BisCover® coating before sterilization (DPE1)
Number of subjects: 48
Study 31166390 — intervention group
Group type: EXPERIMENTAL
Intervention: BisCover® coating after sterilization (DPE2)
Number of subjects: 48
Study 29425211 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive Food Compound (BFC) 40 g daily
Number of subjects: 180
Study 29425211 — intervention group
Group type: COMPARATOR
Intervention: No BFC consumption (Control)
Number of subjects: 180
Study 27621610 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium/formoterol 400/12 µg
Number of subjects: 3394
Study 24750471 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported partial dentures (IRPDs)
Number of subjects: 12
Study 24750471 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-fixed partial dentures (IFPDs)
Number of subjects: 12
Study 24750471 — intervention group
Group type: COMPARATOR
Intervention: Removable partial dentures (RPDs)
Number of subjects: 12
Study 23318241 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based environmental management approach including provision of water container covers, clean-up campaigns, and dissemination of dengue information through schoolchildren.
Number of subjects: 4639
Study 23318241 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based environmental management approach
Number of subjects: 4639
Study 23318241 — intervention group
Group type: COMPARATOR
Intervention: Routine government services and some information education and communication project materials (Control)
Number of subjects: 4639
Study 20590747 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg bid)
Number of subjects: 380
Study 20590747 — intervention group
Group type: COMPARATOR
Intervention: Voglibose (0.2 mg tid)
Number of subjects: 380
Study 17566894 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate
Number of subjects: 137
Study 17566894 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Carbohydrate
Number of subjects: 137
Study 17566894 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 137
Study 15763454 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of oral sustained-release theophylline
Number of subjects: 16
Study 11884816 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose propofol infusion (loading dose of 0.8 mg.kg(‐1) followed by continuous infusion of 30 microg.kg(‐1)min(‐1))
Number of subjects: 90
Study 11884816 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo group)
Number of subjects: 90
Study 10598888 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 2 weeks
Number of subjects: 28
Study 10598888 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic exercise training)
Number of subjects: 28
Study 7551779 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) with active drainage
Number of subjects: 0
Study 7551779 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) with passive drainage
Number of subjects: 0
Study 7551779 — intervention group
Group type: EXPERIMENTAL
Intervention: Air with active drainage
Number of subjects: 0
Study 7551779 — intervention group
Group type: COMPARATOR
Intervention: Air with passive drainage
Number of subjects: 0
Study 2355819 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg; nBB)
Number of subjects: 6
Study 2355819 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (50 mg; sBB)
Number of subjects: 6
Study 2355819 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg; nBB)
Number of subjects: 6
Study 2355819 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 6
Study 2355819 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade (average of Pr, Me, and Pi)
Number of subjects: 6
Study 367086 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. verapamil (0.15 mg/kg body weight)
Number of subjects: 20
Study 367086 — intervention group
Group type: EXPERIMENTAL
Intervention: oral verapamil (80 mg)
Number of subjects: 20
Study 367086 — intervention group
Group type: EXPERIMENTAL
Intervention: oral verapamil (240 mg)
Number of subjects: 20
Study 367086 — intervention group
Group type: EXPERIMENTAL
Intervention: oral verapamil (320 mg)
Number of subjects: 20
Study 367086 — intervention group
Group type: EXPERIMENTAL
Intervention: oral verapamil (400 mg)
Number of subjects: 20
Study 367086 — intervention group
Group type: EXPERIMENTAL
Intervention: chronic oral therapy with progressively increasing doses of verapamil
Number of subjects: 20
Study 30683197 — intervention group
Group type: EXPERIMENTAL
Intervention: vonapanitase
Number of subjects: 349
Study 30683197 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 349
Study 28485774 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis combined with mild hypothermia
Number of subjects: 30
Study 28485774 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial thrombolysis
Number of subjects: 30
Study 26175087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron supplementation (200 mg iron sucrose)
Number of subjects: 41
Study 26175087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 26175087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron supplementation
Number of subjects: 41
Study 23238988 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning along a floor route
Number of subjects: 28
Study 23238988 — intervention group
Group type: COMPARATOR
Intervention: Learning along a column route
Number of subjects: 28
Study 21895505 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation
Number of subjects: 50
Study 21895505 — intervention group
Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 50
Study 19139440 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha‐2b 15 x 10(6) U/m2 IV x 5/7 days weekly x 4 weeks (arm A)
Number of subjects: 353
Study 19139440 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha‐2b 15 x 10(6) U/m2 IV x 5/7 days weekly x 4 weeks followed by IFN‐alpha‐2b 10 x 10(6) U administered subcutaneously three times a week for 48 weeks (arm B)
Number of subjects: 353
Study 19139440 — intervention group
Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 353
Study 17198093 — intervention group
Group type: EXPERIMENTAL
Intervention: Head neutral position
Number of subjects: 108
Study 17198093 — intervention group
Group type: COMPARATOR
Intervention: Head down position
Number of subjects: 108
Study 15098782 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric surgical sealant (CoSeal)
Number of subjects: 54
Study 15098782 — intervention group
Group type: COMPARATOR
Intervention: Gelfoam/thrombin (Control)
Number of subjects: 54
Study 11514824 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure target </=80mmHg
Number of subjects: 18700
Study 11514824 — intervention group
Group type: COMPARATOR
Intervention: Diastolic blood pressure target </=90mmHg
Number of subjects: 18700
Study 11514824 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with diastolic pressure target </=80mmHg
Number of subjects: 18700
Study 9781830 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (50 mg)
Number of subjects: 0
Study 9781830 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release dipyridamole (400 mg/day)
Number of subjects: 0
Study 9781830 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aspirin and dipyridamole
Number of subjects: 0
Study 9781830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7830201 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization splint treatment (experimental group)
Number of subjects: 0
Study 7830201 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study 2533661 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide fraction derived from bovine factor VIII (VUEFFE‐Baldacci)
Number of subjects: 0
Study 2533661 — intervention group
Group type: COMPARATOR
Intervention: Carbazochrome sodium sulphate (Control)
Number of subjects: 0
Study 412061 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dihydroergotamine (DHE)
Number of subjects: 30
Study 412061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30583260 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach Bias Modification (AppBM)
Number of subjects: 131
Study 30583260 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 131
Study 27440869 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100/50mg
Number of subjects: 1064
Study 27440869 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 200/100mg
Number of subjects: 1064